Lechman et al. showed that miR-126 targets the PI3K/AKT/MTOR signaling pathway, preserving leukemia stem cell quiescence and promoting chemotherapy resistance (Chen et al., 2016; Gao et al., 2016; Lechman et al., 2016; Yang et al., 2017). Here, AKT1 is linked to leukemia.